Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®

Biochemical Pharmacology

Volumn 75, Issue 6, 2008, Pages 1302-1312

  Robey, Robert W ^a   Shukla, Suneet ^a   Finley, Elizabeth M ^a   Oldham, Robert K ^b   Barnett, Daryl ^b   Ambudkar, Suresh V ^a   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CBA Research Inc ^*  (United States)

Author keywords

ABCG2; CBT 1 ; Drug resistance; Inhibitor; MRP1; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; BISBENZYLISOQUINOLINE ALKALOID; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; CBT 1; CD56 ANTIGEN; DEPSIPEPTIDE; GLYCOPROTEIN P; IODINE 125; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHEOPHORBIDE; PRAZOSIN; RHODAMINE 123; ROMIDEPSIN; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE;

ARTICLE; BLOOD SAMPLING; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; PHENOTYPE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SERUM;

EID: 39749135394     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.12.001     Document Type: Article

References (43)

1. M.M. Gottesman T. Fojo S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 2002 48 58
2. X.P. Zhang M.K. Ritke J.C. Yalowich M.L. Slovak J.P. Ho K.I. Collins P-glycoprotein mediates profound resistance to bisantrene Oncol Res 6 1994 291 301
3. R.L. Piekarz R.W. Robey Z. Zhan G. Kayastha A. Sayah A.H. Abdeldaim T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood 103 2004 4636 4643
4. S.P.C. Cole G. Bhardwaj J.H. Gerlach J.E. Mackie C.E. Grant K.C. Almquist Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
5. G.D. Kruh H. Zeng P.A. Rea G. Liu Z.S. Chen K. Lee MRP subfamily transporters and resistance to anticancer agents J Bioenerg Biomembr 33 2001 493 501
6. L.A. Doyle D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340 7358
7. W.T. Beck T.M. Grogan C.L. Willman C. Cordon-Cardo D.M. Parham J.F. Kuttesch Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations Cancer Res 56 1996 3010 3020
8. G.D. Leonard T. Fojo S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
9. J.P. Marie D.C. Zhou S. Gurbuxani O. Legrand R. Zittoun MDR1/P-glycoprotein in haematological neoplasms Eur J Cancer 32A 1996 1034 1038
10. G.D. Leonard O. Polgar S.E. Bates ABC transporters and inhibitors: new targets, new agents Curr Opin Investig Drugs 3 2002 1652 1659
11. A.S. Planting P. Sonneveld A. van der Gaast A. Sparreboom M.E. van der Burg G.P. Luyten A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors Cancer Chemother Pharmacol 55 2005 91 99
12. J. Abraham M. Edgerley R. Wilson C. Chen W. Medina L. Hermonstine A phase I study of the novel p-glycoprotein (Pgp) antagonist. XR9576 in combination with vinorelbine Proc Am Soc Clin Oncol 2001 37
13. S.R. Wright A.H. Boag G. Valdimarsson D.R. Hipfner B.G. Campling S.P. Cole Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung Clin Cancer Res 4 1998 2279 2289
14. K. Nooter F.T. Bosman H. Burger K.E. van Wingerden M.J. Flens R.J. Scheper Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer Ann Oncol 7 1996 75 81
15. M. Mohri H. Nitta J. Yamashita Expression of multidrug resistance-associated protein (MRP) in human gliomas J Neurooncol 49 2000 105 115
16. O. Legrand G. Simonin J.Y. Perrot R. Zittoun J.P. Marie Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients Blood 91 1998 4480 4488
17. O. Legrand G. Simonin A. Beauchamp-Nicoud R. Zittoun J.P. Marie Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia Blood 94 1999 1046 1056
18. Z. Benderra A.M. Faussat L. Sayada J.Y. Perrot D. Chaoui J.P. Marie Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias Clin Cancer Res 10 2004 7896 7902
19. C.S. Wilson G.S. Davidson S.B. Martin E. Andries J. Potter R. Harvey Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction Blood 108 2006 685 696
20. R.K. Oldham W.K. Reid H.D. Preisler D. Barnett A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer Cancer Biother Radiopharm 13 1998 71 80
21. R.K. Oldham W.K. Reid D. Barnett Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers Cancer Biother Radiopharm 15 2000 153 159
22. G.-M. Lai Y.-N. Chen L.A. Mickley A.T. Fojo S.E. Bates P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines Int J Cancer 49 1991 696 703
23. R.W. Robey Y. Honjo K. Morisaki T.A. Nadjem S. Runge M. Risbood Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br J Cancer 89 2003 1971 1978
24. M. Muller M. Yong X.H. Peng B. Petre S. Arora S.V. Ambudkar Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1) Biochemistry 41 2002 10123 10132
25. H. Minderman K.L. O’Loughlin L. Pendyala M.R. Baer VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Clin Cancer Res 10 2004 1826 1834
26. R. Robey S. Bakke W. Stein B. Meadows T. Litman S. Patil Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833 Blood 93 1999 306 314
27. P. Skehan R. Storeng D. Scudiero A. Monks J. McMahon D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112
28. S. Shukla R.W. Robey S.E. Bates S.V. Ambudkar The calcium channel blockers 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter ABCG2 Biochemistry 45 2006 8940 8951
29. S.V. Ambudkar Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol 292 1998 504 514
30. P. Mistry A.J. Stewart W. Dangerfield S. Okiji C. Liddle D. Bootle In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator XR9576 Cancer Res 61 2001 749 758
31. U.A. Germann D. Shlyakhter V.S. Mason R.E. Zelle J.P. Duffy V. Galullo Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro Anticancer Drugs 8 1997 125 140
32. M. de Bruin K. Miyake T. Litman R. Robey S.E. Bates Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter MXR Cancer Lett 146 1999 117 126
33. R.W. Robey K. Steadman O. Polgar K. Morisaki M. Blayney P. Mistry Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res 64 2004 1242 1246
34. S.E. Bates Solving the problems of multidrug resistance: ABC transporters in clinical oncology I.B. Holland S.P.C. Cole K. Kuchler C.F. Higgins ABC proteins: from bacteria to man 2002 Elsevier Science London 359 391
35. E.K. Rowinsky L. Smith Y.M. Wang P. Chaturvedi M. Villalona E. Campbell Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP J Clin Oncol 16 1998 2964 2976
36. T. Saeki T. Nomizu M. Toi Y. Ito S. Noguchi T. Kobayashi Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer J Clin Oncol 25 2007 411 417
37. Y. Kimura J. Aoki M. Kohno H. Ooka T. Tsuruo O. Nakanishi P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel Cancer Chemother Pharmacol 49 2002 322 328
38. P. Shrivastava M. Hanibuchi S. Yano P. Parajuli T. Tsuruo S. Sone Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil Cancer Chemother Pharmacol 42 1998 483 490
39. R.A. Peck J. Hewett M.W. Harding Y.M. Wang P.R. Chaturvedi A. Bhatnagar Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin J Clin Oncol 19 2001 3130 3141
40. M.V. Seiden K.D. Swenerton U. Matulonis S. Campos P. Rose G. Batist A phase II study of the MDR inhibitor biricodar (INCEL VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy Gynecol Oncol 86 2002 302 310
41. U.A. Germann P.J. Ford D. Shlyakhter V.S. Mason M.W. Harding Chemosensitization and drug accumulation effects of VX-710, cyclosporin A MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP Anticancer Drugs 8 1997 141 155
42. S.L. Plasschaert D.M. Van Der Kolk E.S. De Bont E. Vellenga W.A. Kamps E.G. De Vries Breast cancer resistance protein (BCRP) in acute leukemia Leuk Lymphoma 45 2004 649 654
43. S. Bates M. Kang B. Meadows S. Bakke P. Choyke M. Merino A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar) Cancer 92 2001 1577 1590